How I treat refractory CRS and ICANS after CAR T-cell therapy
MD Jain, M Smith, NN Shah - … Journal of the American Society of …, 2023 - ashpublications.org
The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …
because of the expanding indications for standard-of-care treatment and the development of …
How I treat unique and difficult-to-manage cases of CAR T-cell therapy–associated neurotoxicity
With growing indications for chimeric antigen receptor (CAR) T-cell therapy, toxicity profiles
are evolving. There is an urgent and unmet need of approaches to optimally manage …
are evolving. There is an urgent and unmet need of approaches to optimally manage …
Intrathecal chemotherapy for management of steroid-refractory CAR T-cell–associated neurotoxicity syndrome
Cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity
syndrome (ICANS) are major limitations of chimeric antigen receptor (CAR) T-cell therapy. 1 …
syndrome (ICANS) are major limitations of chimeric antigen receptor (CAR) T-cell therapy. 1 …
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
C Kotch, D Barrett, DT Teachey - Expert review of clinical …, 2019 - Taylor & Francis
Introduction: Cancer-directed immunotherapies are transforming the landscape in oncology
as new and exciting therapies move from the laboratory to the bedside. Chimeric antigen …
as new and exciting therapies move from the laboratory to the bedside. Chimeric antigen …
Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies
CW Freyer, DL Porter - Journal of Allergy and Clinical Immunology, 2020 - Elsevier
Chimeric antigen receptor T cells are a new and exciting immunotherapeutic approach to
managing cancer, with impressive efficacy but potentially life-threatening inflammatory …
managing cancer, with impressive efficacy but potentially life-threatening inflammatory …
In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy
JG Borrega, P Gödel, MA Rüger, ÖA Onur… - …, 2019 - journals.lww.com
The success of chimeric antigen receptor (CAR)-T cell therapy with impressive response
rates in hematologic malignancies but also promising data in solid tumors came along with …
rates in hematologic malignancies but also promising data in solid tumors came along with …
Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
LL Riegler, GP Jones, DW Lee - Therapeutics and clinical risk …, 2019 - Taylor & Francis
With immunotherapy innovations for cancer treatment, in particular chimeric antigen receptor
(CAR) T cells, becoming more successful and prevalent, strategies to mitigate and manage …
(CAR) T cells, becoming more successful and prevalent, strategies to mitigate and manage …
[引用][C] How I manage: pathophysiology and management of toxicity of chimeric antigen receptor T-cell therapies
PM Reagan, SS Neelapu - Journal of Clinical Oncology, 2021 - ascopubs.org
The development of immune effector cell (IEC) therapy spans several decades, with early
activity in advanced cancer reported in the late 1980s. 1, 2 Chimeric antigen receptors …
activity in advanced cancer reported in the late 1980s. 1, 2 Chimeric antigen receptors …
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
P Karschnia, JT Jordan, DA Forst… - Blood, The Journal …, 2019 - ashpublications.org
Chimeric antigen receptor (CAR) T cells have emerged as a promising class of cell-based
immunotherapy in refractory malignancies. Neurotoxicity represents a common and …
immunotherapy in refractory malignancies. Neurotoxicity represents a common and …
Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy
UH Acharya, T Dhawale, S Yun… - Expert Review of …, 2019 - Taylor & Francis
Introduction: Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated
remarkable anti-tumor activity in B-cell malignancies and is under investigation in other …
remarkable anti-tumor activity in B-cell malignancies and is under investigation in other …